Artal Group S.A. Buys BioNTech SE, Alnylam Pharmaceuticals Inc, Morphic Holding Inc, Sells The Medicines Co, NVIDIA Corp, Avantor Inc

• New Purchases: BNTX, MORF, PYPL, SWTX, HARP, RETA, IMUX, PRTA, KRTX, DOYU, NTLA, CRIS,
• Added Positions: ALNY, ARGX, EPZM, ARAV, AGIO, FGEN, XNCR, CLVS, FOLD, Z, ATRA, STNE, SELB, SRRK, KURA, AXDX, SLDB,
• Reduced Positions: AVTR, BPMC, XLRN, DCPH, REAL, DRNA, ASND, TPTX, IOVA, KRYS, TGTX, BGNE, TBIO, SPRO,
• Sold Out: MDCO, NVDA, GBT, MRTX, FIS, BOLD, NKTR, ARQL, TORC, NIO, GRTS, SQ, AVRO,

For the details of Artal Group S.A.'s stock buys and sells, go to https://www.gurufocus.com/guru/artal+group+s.a./current-portfolio/portfolio

1. WW International Inc (WW) - 14,818,300 shares, 22.15% of the total portfolio.
2. Lexicon Pharmaceuticals Inc (LXRX) - 60,240,864 shares, 9.78% of the total portfolio.
3. Alnylam Pharmaceuticals Inc (ALNY) - 1,000,000 shares, 4.51% of the total portfolio. Shares added by 42.86%
4. BeiGene Ltd (BGNE) - 640,000 shares, 4.15% of the total portfolio. Shares reduced by 1.54%
5. Morgan Stanley (MS) - 2,000,000 shares, 4.00% of the total portfolio.

Artal Group S.A. initiated holding in BioNTech SE. The purchase prices were between $12.75 and $36.91, with an estimated average price of $22.59. The stock is now traded at around $30.55. The impact to a portfolio due to this purchase was 3.48%. The holding were 2,628,130 shares as of .

Artal Group S.A. initiated holding in Morphic Holding Inc. The purchase prices were between $13.02 and $19.5, with an estimated average price of $15.61. The stock is now traded at around $15.75. The impact to a portfolio due to this purchase was 1.22%. The holding were 1,819,186 shares as of .

Artal Group S.A. initiated holding in PayPal Holdings Inc. The purchase prices were between $96.64 and $109.75, with an estimated average price of $104.36. The stock is now traded at around $116.50. The impact to a portfolio due to this purchase was 0.85%. The holding were 200,000 shares as of .

Artal Group S.A. initiated holding in SpringWorks Therapeutics Inc. The purchase prices were between $17.74 and $39.52, with an estimated average price of $23.67. The stock is now traded at around $33.56. The impact to a portfolio due to this purchase was 0.53%. The holding were 350,000 shares as of .

Artal Group S.A. initiated holding in Harpoon Therapeutics Inc. The purchase prices were between $12.94 and $20.58, with an estimated average price of $15.34. The stock is now traded at around $14.66. The impact to a portfolio due to this purchase was 0.49%. The holding were 850,000 shares as of .

Artal Group S.A. initiated holding in Reata Pharmaceuticals Inc. The purchase prices were between $74.57 and $217.92, with an estimated average price of $184.77. The stock is now traded at around $196.52. The impact to a portfolio due to this purchase was 0.4%. The holding were 50,000 shares as of .

Artal Group S.A. added to a holding in Alnylam Pharmaceuticals Inc by 42.86%. The purchase prices were between $75.49 and $124.23, with an estimated average price of $100.64. The stock is now traded at around $122.37. The impact to a portfolio due to this purchase was 1.35%. The holding were 1,000,000 shares as of .

Artal Group S.A. added to a holding in argenx SE by 75.00%. The purchase prices were between $106.59 and $164.21, with an estimated average price of $135.82. The stock is now traded at around $156.35. The impact to a portfolio due to this purchase was 0.94%. The holding were 350,000 shares as of .

Artal Group S.A. added to a holding in Epizyme Inc by 50.00%. The purchase prices were between $9.77 and $24.6, with an estimated average price of $15.05. The stock is now traded at around $21.69. The impact to a portfolio due to this purchase was 0.72%. The holding were 2,250,000 shares as of .

Artal Group S.A. added to a holding in Aravive Inc by 237.50%. The purchase prices were between $6.21 and $14.02, with an estimated average price of $8.92. The stock is now traded at around $9.07. The impact to a portfolio due to this purchase was 0.51%. The holding were 1,350,000 shares as of .

Artal Group S.A. added to a holding in Agios Pharmaceuticals Inc by 50.00%. The purchase prices were between $30.08 and $50.59, with an estimated average price of $38.07. The stock is now traded at around $49.71. The impact to a portfolio due to this purchase was 0.37%. The holding were 600,000 shares as of .

Artal Group S.A. added to a holding in FibroGen Inc by 122.22%. The purchase prices were between $34.58 and $48.06, with an estimated average price of $40.98. The stock is now traded at around $43.75. The impact to a portfolio due to this purchase was 0.37%. The holding were 400,000 shares as of .

Artal Group S.A. sold out a holding in The Medicines Co. The sale prices were between $49.68 and $84.94, with an estimated average price of $67.5.

Artal Group S.A. sold out a holding in NVIDIA Corp. The sale prices were between $173.04 and $239.37, with an estimated average price of $209.21.

Artal Group S.A. sold out a holding in Global Blood Therapeutics Inc. The sale prices were between $45.7 and $81.86, with an estimated average price of $59.89.

Artal Group S.A. sold out a holding in Mirati Therapeutics Inc. The sale prices were between $70.76 and $128.86, with an estimated average price of $97.36.

Artal Group S.A. sold out a holding in Audentes Therapeutics Inc. The sale prices were between $25.55 and $59.84, with an estimated average price of $37.91.

Artal Group S.A. sold out a holding in Fidelity National Information Services Inc. The sale prices were between $125.44 and $139.75, with an estimated average price of $134.26.